This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

G1 Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:G1H Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
05 Jul 24	Sell€1,221	John Umstead	Individual	527	€2.32
05 Jul 24	Sell€5,733	Rajesh Malik	Individual	2,475	€2.32
05 Jul 24	Sell€5,733	Terry Murdock	Individual	2,475	€2.32
05 Jul 24	Sell€17,748	John Bailey	Individual	7,662	€2.32
05 Jul 24	Sell€6,111	Mark Avagliano	Individual	2,638	€2.32
05 Jul 24	Sell€3,097	Andrew Perry	Individual	1,337	€2.32
23 May 24	Sell€22,972	Monica Thomas	Individual	5,826	€3.94
13 May 24	Sell€165,307	John Bailey	Individual	37,258	€4.44
13 May 24	Sell€36,165	Terry Murdock	Individual	8,151	€4.44
13 May 24	Sell€36,165	John Umstead	Individual	8,151	€4.44
13 May 24	Sell€36,165	Andrew Perry	Individual	8,151	€4.44
13 May 24	Sell€36,165	Mark Avagliano	Individual	8,151	€4.44
13 May 24	Sell€36,165	Rajesh Malik	Individual	8,151	€4.44
18 Mar 24	Sell€18,168	John Umstead	Individual	6,547	€2.77

Insider Trading Volume

Insider Buying: G1H insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of G1H?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	1,292,778	2.44%
Hedge Funds	5,179,529	9.79%
VC/PE Firms	7,166,704	13.6%
General Public	19,030,369	36%
Institutions	20,220,995	38.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.

Top Shareholders

Top 25 shareholders own 56.42% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
9.79%	Beryl Capital Management LLC	5,179,529	€33.3m	0%	7.87%
7.97%	Eshelman Ventures, LLC	4,216,074	€27.1m	0%	100.0%
5.83%	BlackRock, Inc.	3,082,031	€19.8m	359%	no data
5.58%	MedImmune Ventures, Inc.	2,950,630	€19.0m	0%	100.0%
4.71%	The Vanguard Group, Inc.	2,491,109	€16.0m	19.7%	no data
2.58%	Woodline Partners LP	1,362,354	€8.8m	0%	0.09%
2.35%	Renaissance Technologies LLC	1,245,180	€8.0m	37.8%	0.01%
2.04%	Geode Capital Management, LLC	1,079,645	€6.9m	113%	no data
1.75%	Acadian Asset Management LLC	928,205	€6.0m	114%	0.02%
1.57%	State Street Global Advisors, Inc.	827,956	€5.3m	414%	no data
1.51%	Qube Research & Technologies Ltd	800,511	€5.1m	147%	0.01%
1.51%	Raymond James Financial Inc., Asset Management Arm	797,677	€5.1m	-0.64%	no data
1.45%	D. E. Shaw & Co., L.P.	767,066	€4.9m	-2.32%	0.01%
1.09%	Connor, Clark & Lunn Investment Management Ltd.	576,354	€3.7m	39.4%	0.02%
1.04%	Fredric Eshelman	550,000	€3.5m	0%	no data
0.88%	Jacobs Levy Equity Management Inc	463,593	€3.0m	22.7%	0.01%
0.8%	abrdn plc	423,869	€2.7m	0%	no data
0.75%	Bridgeway Capital Management, LLC	398,043	€2.6m	108%	0.05%
0.74%	Morgan Stanley, Investment Banking and Brokerage Investments	392,184	€2.5m	124%	no data
0.58%	Two Sigma Investments, LP	308,825	€2.0m	-7.57%	0.01%
0.4%	Two Sigma Advisers, LP	211,700	€1.4m	15.2%	no data
0.38%	Eversept Partners, L.P.	199,963	€1.3m	0%	0.1%
0.38%	Readystate Asset Management LP	199,358	€1.3m	0%	0.12%
0.37%	John Bailey	196,287	€1.3m	4.35%	no data
0.36%	STRS Ohio	192,700	€1.2m	0%	0.01%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/09/18 03:25
End of Day Share Price	2024/09/18 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

G1 Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Harshita Polishetty	B. Riley Securities, Inc.
Dane Leone	BTIG
Charles Butler	D. Boral Capital LLC.